Scintica Supports First European Sale of MH3D Alpha-SPECT™ Mini at Minerva Imaging

[April, 2026]

London, Canada  – Scintica is pleased to announce its role in supporting the first European sale of the Alpha-SPECT Mini™ system from MH3D, Inc. at Minerva Imaging.

Minerva Imaging is an integrated CRO/CDMO that partners with pharmaceutical and biotechnology companies developing targeted radionuclide therapies, including rapidly emerging alpha-emitting therapeutics such as Actinium-225. The addition of the Alpha-SPECT™ Mini enhances their ability to support clients with advanced preclinical imaging, particularly where accurate in vivo biodistribution and daughter isotope analysis are essential.

The Alpha-SPECT™ Mini is specifically designed for high-sensitivity imaging of alpha-emitting radiopharmaceuticals. Its CZT-based detector technology enables precise detection, separation, and quantification of both parent radionuclides and their decay products, providing critical insights for companies advancing next-generation alpha therapies.

As a commercial partner and global distributor of MH3D systems, Scintica is proud to support Minerva Imaging in expanding its capabilities to serve the growing alpha therapy market. This sale marks a key milestone in bringing specialized alpha-imaging solutions to Europe and supporting the broader ecosystem of companies investing in this field.

Advancing Preclinical SPECT Research 

The Alpha-SPECT Mini™ is a trusted solution for research teams requiring precision, flexibility, and efficiency across a wide range of molecular imaging applications.  Its advanced capabilities support cutting-edge work in oncology, neurology, cardiovascular research, and radiotheranostics.